The A2 Milk Company Ltd – Enhances stake in Synlait Milk Limited

A2 Milk

The A2 Milk Company Limited’s (ASX: A2M) stock edged up 0.837 per cent on August 03, 2018 after the announcement of lift in stake in its partner, Synlait Milk Limited. According to the release, the group will lift its shareholdings in ordinary shares of Synlait Milk Limited from 9.11% to 17.39%. The increased investment represents a strong relationship and long-term commitment of both organisations. The group revealed that it will acquire extra 8.3 per cent of the fully paid ordinary shares through its subsidiary in Synlait Milk for NZ $14,840,527. Further, the group is eyeing the stake from Mitsui & Co at a price of NZ $10.90 per share; and this would be for the total consideration of about NZ $161.8 Mn. This will be a modest discount to the NZX one-month volume weighted average price of NZ $11.16.

This move comes after the reaffirmation by A2M on its infant formula and other nutritional products supply agreement with Synlait as per July 2018 update. The supply agreement has been flagged to be cornerstone of its commercial relationship with Synlait. The investment enhancement is also as per A2M’s commitment to long-term supply arrangements with high quality partners including Fonterra Co-operative Group.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report